Hence, several studies have provided a valuable overview of the genes and gene products (α-SMA, HSP47, COL1A1, TIMP-1, MMP-7, and MMP-1) that are dysregulated in preclinical models of fibrotic liver diseases and/or in fibrotic human liver tissues, thereby offering relevant efficacy endpoints to assess the antifibrotic potential of experimental compounds [17]. The gene discussed is TIMP1; the disease is liver disorder.